Enzymatica
2.54 SEK
+2.01 %
Less than 1K followers
ENZY
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Enzymatica
EV/S
Median 2019-2021
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 3.67 | 17.29 | 8.08 | 4.16 | 3.65 | 1.58 | 1.90 |
| Shares | 154.5 | 154.5 | 157.6 | 177.6 | 177.6 | 242.7 | 242.7 |
| Market cap | 567.0 | 2,670.8 | 1,273.6 | 739.2 | 648.0 | 383.5 | 461.2 |
| Enterprise value | 540.2 | 2,659.5 | 1,244.6 | - | - | - | - |
| EV/S | 8.8 | 23.9 | 21.7 | - | - | - | - |
| EV/EBITDA | neg. | neg. | neg. | - | - | - | - |
| EV/EBIT | neg. | neg. | neg. | - | - | - | - |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 4.76 | 25.04 | 10.19 | 5.85 | 8.46 | 2.17 | 3.71 |
| P/S | 9.2 | 24.0 | 22.2 | 15.1 | 12.7 | 8.4 | 8.6 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 80.7 % | 65.8 % | 79.6 % | 72.4 % | 60.8 % | 90.3 % | 87.5 % |
| Gearing ratio | 2.1 % | 12.0 % | 1.2 % | 17.7 % | 34.1 % | 1.2 % | 0.8 % |